Intimation about Change in Status of Acutaas Chemicals Electrolytes Private Limited from Wholly Owned Subsidiary to Subsidiary of Acutaas Chemicals Limited
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Acutaas Chemicals' board approved a preferential allotment of 1,111 equity shares in its wholly-owned subsidiary ACEPL to A.R.Z. Pharma Ltd at Rs. 52,490 per share (including Rs. 52,480 share premium). The shares were issued on a partly paid-up basis with 25% called on application (~Rs. 1.46 crore) and the remaining 75% (~Rs. 4.37 crore) callable by May 2, 2027. Following the allotment, Acutaas Chemicals' stake in ACEPL diluted from 100% to 90%, causing ACEPL to cease being a wholly-owned subsidiary. Management control of ACEPL remains with Acutaas Chemicals, and the number of equity shares held by the company stayed unchanged at 10,000. A.R.Z. Pharma is based in Netanya, Israel. No benefit to the promoter or promoter group was reported.
The 10% stake sale to an external investor reduces the subsidiary from wholly-owned to associate subsidiary status, though control is retained. This may signal strategic intent to bring in a partner or future expansion plans for ACEPL without triggering any open offer obligations since dilution was below the 25% threshold.